NCT07343778已完成3 期
A Single-Arm, Open-Label, Multicenter Phase III Clinical Trial to Evaluate the Safety of Hydronidone Capsules in Patients With Hepatic Fibrosis and Liver Cirrhosis
Beijing Continent Pharmaceutical Co, Ltd.2 个研究点 分布在 1 个国家目标入组 337 人开始时间: 2026年3月16日最近更新:
干预措施
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 337
- 试验地点
- 2
- 主要终点
- Any adverse events occurring in study participants following drug administration.
研究概览
简要总结
This is a single-arm, multicenter, open-label Phase III clinical trial to evaluate the safety and tolerability of high-dose hydronidone capsules in patients with hepatic fibrosis and cirrhosis. Eligible participants will be sequentially enrolled to receive hydronidone capsules 120 mg three times daily (TID) for 28 consecutive days. Participants will return to the hospital on Day 28 after the first dose for a follow-up safety assessment. All adverse events (AEs) and concomitant medications must be recorded during the study period. Participants who complete the Day 28 follow-up visit are considered to have completed the study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participants fully understand the study, voluntarily participate, and have signed the informed consent form (ICF).
- •Aged ≥18 years, regardless of gender.
- •Have a confirmed diagnosis of hepatic fibrosis or cirrhosis based on either:
- •A prior percutaneous liver biopsy (results within 1 year prior to enrollment are acceptable); or
- •Imaging findings (Fibroscan, Fibrotouch, or ultrasound, with results within 3 months prior to enrollment acceptable).
- •Alanine aminotransferase (ALT) < 8 × upper limit of normal (ULN).
- •Female participants of childbearing potential must have a negative serum pregnancy test. Furthermore, the participant or their partner must agree to employ highly effective contraceptive methods from the start of the trial until 6 months after the last dose of the study drug.
排除标准
- •History of major upper gastrointestinal hemorrhage within the past 3 months prior to enrollment, or the presence of gastrointestinal disorders affecting drug absorption at the time of screening.
- •Total bilirubin (TBIL) > 3 × upper limit of normal (ULN), or ALT > 3 × ULN but < 8 × ULN and TBIL > 2 × ULN.
- •Alpha-Fetoprotein (AFP) > 100 μg/L, even in the absence of clinical indications of hepatocellular carcinoma.
- •Platelet count (PLT) ≤ 50 × 10⁹/L; Prothrombin activity (PTA) < 50% or International Normalized Ratio (INR) > 1.
- •Active bacterial, viral (excluding chronic viral hepatitis B or C), fungal, or parasitic infection within 4 weeks prior to screening, or any infectious event requiring systemic anti-infective therapy.
- •Positive test for Human Immunodeficiency Virus antibody (HIV-Ab).
- •History of definite malignant tumors, or clinically significant dysfunction of major organs including heart, lungs, or kidneys, as well as clinically significant severe hepatic dysfunction unrelated to the underlying liver disease (e.g., manifestations of decompensated cirrhosis).
- •Pregnant or lactating women.
- •Participation in any other clinical trial and receipt of investigational drugs within 3 months prior to screening.
- •Any other condition deemed by the investigator as unsuitable for enrollment or likely to prevent completion of the study.
研究组 & 干预措施
Hydronitone Capsules group
Experimental
Eligible subjects who passed screening were enrolled sequentially in this study and received Hydronidone Capsules 120mg TID for 28 consecutive days.
干预措施: Hydronidone Capsules (Drug)
结局指标
主要结局
Any adverse events occurring in study participants following drug administration.
时间窗: 28 days
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
招募中
2 期
9MW2821 Combined With Toripalimab in Perioperative Patients With Urothelial CancerNCT07314723Mabwell (Shanghai) Bioscience Co., Ltd.90
招募中
1 期
A Clinical Trial of EHT102 Injection in Pediatric Patients With Biallelic hOTOF MutationsNCT07288580Shanghai Euhearing Therapeutics Co., Ltd30
招募中
3 期
A Phase III Study Comparing HRS-4357 With Novel Androgen Receptor Pathway Inhibitors in Patients With Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate CancerNCT07311694Jiangsu HengRui Medicine Co., Ltd.370
Enrolling By Invitation
1 期
A Phase I Clinical Trial to Evaluate the Safety of Different Immunization Schedules of a Lyophilized Human Rabies Vaccine (Human Diploid Cell)NCT07338786Changchun BCHT Biotechnology Co.80
招募中
2 期
A Study to Evaluate the Efficacy and Safety of IBI302inSubjects With nAMDNCT07275840Innovent Biologics Technology Limited (Shanghai R&D Center)800